-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Te2Uzgzf6e7DjUd7w3Ig2xygmwscNGuiXN4FmpDTRoOuTP0LNnbllODwemKxp0e2
 bxpeatHspP76lglB5F//gA==

<SEC-DOCUMENT>0000012208-06-000018.txt : 20060803
<SEC-HEADER>0000012208-06-000018.hdr.sgml : 20060803
<ACCEPTANCE-DATETIME>20060803162915
ACCESSION NUMBER:		0000012208-06-000018
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20060630
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20060803
DATE AS OF CHANGE:		20060803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO RAD LABORATORIES INC
		CENTRAL INDEX KEY:			0000012208
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				941381833
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-07928
		FILM NUMBER:		061002404

	BUSINESS ADDRESS:	
		STREET 1:		1000 ALFRED NOBEL DR
		CITY:			HERCULES
		STATE:			CA
		ZIP:			94547
		BUSINESS PHONE:		5107247000
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k063006.htm
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>Bio-Rad Laboratories, Inc</TITLE>
<META NAME="author" CONTENT="Stephanie Trudrung">
<META NAME="date" CONTENT="08/03/2006">
</HEAD>
<BODY style="line-height:12pt; font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:468pt"><P style="margin:0pt"><BR></P>
<TABLE style="font-size:10pt" cellspacing=0><TR><TD width=468></TD></TR>
<TR><TD valign=top width=624><P style="line-height:13pt; margin:0pt; font-size:11pt" align=center>UNITED STATES</P>
<P style="line-height:13pt; margin:0pt; font-size:11pt" align=center>SECURITIES AND EXCHANGE COMMISSION</P>
<P style="line-height:13pt; margin:0pt; font-size:11pt" align=center>Washington, D.C. &nbsp;20549</P>
<P style="margin:0pt" align=center><BR></P>
<P style="line-height:13pt; margin:0pt; font-size:11pt" align=center>Form 8-K</P>
<P style="margin:0pt" align=center><BR></P>
<P style="line-height:13pt; margin:0pt; font-size:11pt" align=center>CURRENT REPORT</P>
<P style="line-height:13pt; margin:0pt; font-size:11pt" align=center>PURSUANT TO SECTION 13 OR 15(D)OF THE SECURITIES EXCHANGE ACT OF 1934</P>
</TD></TR>
<TR><TD valign=top width=624><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD style="border-bottom:0.5pt solid #000000" valign=top width=624><P style="line-height:13pt; margin:0pt; font-size:11pt" align=center>Date of Report<FONT FACE="Symbol">:</FONT> &nbsp;August 3, 2006</P>
</TD></TR>
<TR><TD valign=top width=624><P style="line-height:13pt; margin:0pt; font-size:11pt" align=center>(Date of earliest event reported)</P>
</TD></TR>
</TABLE>
<P style="margin:0pt" align=center><BR></P>
<TABLE style="font-size:10pt" cellspacing=0><TR><TD width=36></TD><TD width=432></TD></TR>
<TR><TD valign=top width=48><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=576><P style="line-height:13pt; margin:0pt; font-size:11pt" align=center>BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
</TABLE>
<P style="line-height:13pt; margin:0pt; padding-left:36pt; font-size:11pt" align=center>(Exact name of registrant as specified in its charter)</P>
<P style="margin:0pt" align=center><BR></P>
<P style="line-height:13pt; margin:0pt; padding-left:14.4pt; font-size:11pt" align=center>Commission file number <U>1-7928</U></P>
<P style="margin:0pt" align=center><BR></P>
<TABLE style="font-size:10pt" cellspacing=0><TR><TD width=262.75></TD><TD width=13.15></TD><TD width=14.4></TD><TD width=177.7></TD></TR>
<TR><TD style="border-bottom:0.5pt solid #000000" valign=top width=350.333><P style="line-height:13pt; margin:0pt; font-size:11pt" align=center>Delaware</P>
</TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=17.533><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=256.133 colspan=2><P style="margin:0pt; font-size:11pt" align=center>94-1381833</P>
</TD></TR>
<TR><TD valign=top width=350.333><P style="margin:0pt; font-size:11pt" align=center>(State or other jurisdiction of incorporation or organization)</P>
</TD><TD valign=top width=17.533><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=256.133 colspan=2><P style="margin:0pt; font-size:11pt" align=center>(I.R.S. Employer Identification No.)</P>
</TD></TR>
<TR><TD valign=top width=350.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=17.533><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=256.133 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD style="border-bottom:0.5pt solid #000000" valign=top width=350.333><P style="margin:0pt; font-size:11pt" align=center>1000 Alfred Nobel Drive, Hercules, California</P>
</TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=17.533><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=256.133 colspan=2><P style="margin:0pt; font-size:11pt" align=center>94547</P>
</TD></TR>
<TR><TD valign=top width=367.867 colspan=2><P style="margin:0pt; font-size:11pt" align=center>(Address of principal executive offices)</P>
</TD><TD valign=top width=19.2><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=236.933><P style="margin:0pt; font-size:11pt" align=center>(Zip Code)</P>
</TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD style="border-bottom:0.5pt solid #000000" valign=top width=624 colspan=4><P style="margin:0pt; font-size:11pt" align=center>(510) 724-7000</P>
</TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="margin:0pt; font-size:11pt" align=center>Registrant's telephone number, including area code</P>
</TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="line-height:14pt; margin-top:0pt; margin-bottom:-14pt; font-size:11pt">ITEM 2.02.</P>
<P style="margin:0pt; text-indent:72pt; font-size:11pt">RESULTS OF OPERATIONS AND FINANCIAL CONDITION.</P>
</TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="margin:0pt; font-size:11pt">The information in Item 2.02 of the Report, including Exhibit 99.1 attached hereto, is being furnished</P>
</TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="margin:0pt; font-size:11pt">pursuant to Item 2.02 of Form 8-K. &nbsp;Consequently, it is not deemed &#147;filed&#148; for the purposes of Section 18</P>
</TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="margin:0pt; font-size:11pt">of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that </P>
</TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="margin:0pt; font-size:11pt">section. &nbsp;It may only be incorporated by reference in another filing under the Exchange Act or</P>
</TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="margin:0pt; font-size:11pt">Securities Act of 1933, as amended, if such subsequent filing specifically references this Form 8-K.</P>
</TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="margin:0pt; font-size:11pt">On August 3, 2006, Bio-Rad Laboratories, Inc. announced its results of operations and financial</P>
</TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="margin:0pt; font-size:11pt">condition as of and for the quarter ended June 30, 2006. &nbsp;A copy of the press release is attached</P>
</TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="margin:0pt; font-size:11pt">hereto as Exhibit 99.1 and is incorporated herein by reference.</P>
</TD></TR>
<TR><TD valign=top width=624 colspan=4><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR>
<BR></P>
<P style="margin:0pt; page-break-before:always"><BR></P>
<P style="margin:0pt"><BR></P>
<TABLE style="font-size:10pt" cellspacing=0><TR><TD width=63></TD><TD width=396></TD></TR>
<TR><TD valign=top width=612 colspan=2><P style="line-height:13pt; margin-top:0pt; margin-bottom:-13pt; font-size:11pt">Item 9.01</P>
<P style="line-height:13pt; margin:0pt; text-indent:72pt; font-size:11pt">FINANCIAL STATEMENTS AND EXHIBITS</P>
</TD></TR>
<TR><TD valign=top width=84><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=528><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=84><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=528><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=84><P style="line-height:13pt; margin:0pt; font-family:Symbol; font-size:11pt"><FONT FACE="Symbol">(</FONT><FONT FACE="Times New Roman">c</FONT>)</P>
</TD><TD valign=top width=528><P style="line-height:13pt; margin:0pt; font-size:11pt"><FONT FACE="Times New Roman">Exhibits</FONT></P>
</TD></TR>
<TR><TD valign=top width=84><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=528><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="margin:0pt"><BR></P>
<TABLE style="font-size:10pt" cellspacing=0><TR><TD width=63></TD><TD width=11.8></TD><TD width=384.2></TD></TR>
<TR><TD valign=top width=84><P style="line-height:13pt; margin:0pt; font-size:11pt">Exhibit </P>
</TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=512.267><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD style="border-bottom:0.5pt solid #000000" valign=top width=84><P style="line-height:13pt; margin:0pt; font-size:11pt">Number</P>
</TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=512.267><P style="line-height:13pt; margin:0pt; font-size:11pt">Description</P>
</TD></TR>
<TR><TD valign=top width=84><P style="line-height:13pt; margin:0pt; font-size:11pt">99.1</P>
</TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=512.267><P style="line-height:13pt; margin:0pt; font-size:11pt">Press Release for second quarter 2006 financial results of</P>
</TD></TR>
<TR><TD valign=top width=84><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=512.267><P style="line-height:13pt; margin:0pt; font-size:11pt">Bio-Rad Laboratories, Inc., dated August 3, 2006. &nbsp;This exhibit is</P>
</TD></TR>
<TR><TD valign=top width=84><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=512.267><P style="line-height:13pt; margin:0pt; font-size:11pt">being furnished pursuant to Item 2.02 of Form 8-K.</P>
</TD></TR>
</TABLE>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<TABLE style="font-size:10pt" cellspacing=0><TR><TD width=473.4></TD></TR>
<TR><TD valign=top width=631.2><P style="line-height:13pt; margin:0pt; font-size:11pt" align=center>SIGNATURES</P>
</TD></TR>
<TR><TD valign=top width=631.2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=631.2><P style="line-height:13pt; margin:0pt; font-size:11pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly</P>
</TD></TR>
<TR><TD valign=top width=631.2><P style="line-height:13pt; margin:0pt; font-size:11pt">caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
</TD></TR>
</TABLE>
<P style="margin:0pt"><BR></P>
<TABLE style="font-size:10pt" cellspacing=0 align=center><TR><TD width=137.7></TD><TD width=189></TD></TR>
<TR><TD valign=top width=183.6><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=252><P style="line-height:13pt; margin:0pt; font-size:11pt">BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
<TR><TD valign=top width=183.6><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=252><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=183.6><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=252><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=183.6><P style="line-height:13pt; margin:0pt; font-size:11pt">Date: &nbsp;<U>August 3, 2006</U></P>
</TD><TD valign=top width=252><P style="line-height:13pt; margin:0pt; font-size:11pt"><U>/s/ Christine A. Tsingos</U></P>
</TD></TR>
<TR><TD valign=top width=183.6><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=252><P style="line-height:13pt; margin:0pt; font-size:11pt">Christine A. Tsingos </P>
</TD></TR>
<TR><TD valign=top width=183.6><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=252><P style="line-height:13pt; margin:0pt; font-size:11pt">Vice President and</P>
</TD></TR>
<TR><TD valign=top width=183.6><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=252><P style="line-height:13pt; margin:0pt; font-size:11pt">&nbsp;&nbsp;Chief Financial Officer</P>
</TD></TR>
</TABLE>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<TABLE style="font-size:10pt" cellspacing=0><TR><TD width=63></TD><TD width=11.8></TD><TD width=384.2></TD></TR>
<TR><TD valign=top width=612 colspan=3><P style="line-height:13pt; margin:0pt; font-size:11pt" align=center>EXHIBIT INDEX</P>
</TD></TR>
<TR><TD valign=top width=84><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=512.267><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=84><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=512.267><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=84><P style="line-height:13pt; margin:0pt; font-size:11pt">Exhibit </P>
</TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=512.267><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD style="border-bottom:0.5pt solid #000000" valign=top width=84><P style="line-height:13pt; margin:0pt; font-size:11pt">Number</P>
</TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=512.267><P style="line-height:13pt; margin:0pt; font-size:11pt">Description</P>
</TD></TR>
<TR><TD valign=top width=84><P style="line-height:13pt; margin:0pt; font-size:11pt">99.1</P>
</TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=512.267><P style="line-height:13pt; margin:0pt; font-size:11pt">Press Release for second quarter 2006 financial results of</P>
</TD></TR>
<TR><TD valign=top width=84><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=512.267><P style="line-height:13pt; margin:0pt; font-size:11pt">Bio-Rad Laboratories, Inc., dated August 3, 2006. &nbsp;This exhibit is</P>
</TD></TR>
<TR><TD valign=top width=84><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=512.267><P style="line-height:13pt; margin:0pt; font-size:11pt">being furnished pursuant to Item 2.02 of Form 8-K.</P>
</TD></TR>
</TABLE>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR>
<BR></P>
</DIV></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1 CHARTER
<SEQUENCE>2
<FILENAME>exh991063006.htm
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>PART 1 &#8211; FINANCIAL INFORMATION</TITLE>
<META NAME="author" CONTENT="Stephanie Trudrung">
<META NAME="date" CONTENT="07/10/2006">
</HEAD>
<BODY style="line-height:12pt; font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:453.6pt"><P style="margin:0pt" align=right><U>Exhibit 99.1</U></P>
<P style="margin:0pt" align=right><BR></P>
<P style="line-height:11pt; margin:0pt; padding-right:32.4pt; font-family:Arial; font-size:9pt"><FONT FACE="Arial"><B><I>FOR IMMEDIATE RELEASE</I></B></FONT></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="line-height:14pt; margin:0pt; font-family:HelveticaNeueLT Std; font-size:12pt" align=center><FONT FACE="HelveticaNeueLT Std"><B>BIO-RAD LABORATORIES REPORTS SECOND-QUARTER RESULTS</B></FONT></P>
<P style="margin:0pt" align=justify><BR></P>
<P style="margin:0pt" align=justify><BR></P>
<P style="line-height:17pt; margin:0pt; font-family:HelveticaNeueLT Std"><B>HERCULES, CA &#150; August 3, 2006 &#150;</B> Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb), a multinational manufacturer and distributor of life science research products and clinical diagnostics, announced financial results today for the second quarter ended June 30, 2006.<FONT COLOR=#0000FF> </FONT>Second-quarter revenues from continuing operations were<FONT COLOR=#0000FF> </FONT>$317.7 million, up 9.1% compared to the<FONT COLOR=#0000FF> </FONT>$291.3 million reported for the second quarter of 2005.<FONT COLOR=#0000FF> </FONT>Included in this figure is one-time additional revenue of $11.7 million resulting from a licensing settlement agreement reached with bioM&#233;rieux, which had a favorable impact on both the second quarter and year-to-date figures for 2006. On a currency-neutral basis, revenues increased 9.7% compared to the same period last year or 5.6% excluding the settlement. This sales increase was the result of growt
h across product areas in both the Life Science and Clinical Diagnostics segments. Income from continuing operations for the quarter was<FONT COLOR=#0000FF> </FONT>$32<FONT COLOR=#0000FF>.</FONT>3 million<FONT COLOR=#0000FF> </FONT>compared to<FONT COLOR=#0000FF> </FONT>$18.4 million during the second quarter last year.<FONT COLOR=#0000FF> </FONT>At 58.1%,<FONT COLOR=#0000FF> </FONT>second-quarter gross margin from continuing operations was markedly higher than the 55.1% reported for the second quarter of 2005.<FONT COLOR=#0000FF> </FONT>Excluding the impact of the bioM&#233;rieux settlement, gross margin was 56.5%.</P>
<P style="margin:0pt"><BR></P>
<P style="line-height:17pt; margin:0pt; font-family:HelveticaNeueLT Std">Year-to-date revenues from continuing operations grew by<FONT COLOR=#0000FF> </FONT>6.0% to $626.1 million compared to the same period last year.<FONT COLOR=#0000FF> </FONT>Normalizing for the impact of currency effects, growth<FONT COLOR=#0000FF> </FONT>was 9.0%.<FONT COLOR=#0000FF> </FONT>Income from continuing operations increased by 32.5% to<FONT COLOR=#0000FF> </FONT>$63.5 million, or $2.41 per share compared to<FONT COLOR=#0000FF> </FONT>$47.9 million, or $1.85<FONT COLOR=#0000FF> </FONT>per share,<B> </B>for the first six months of 2005.<FONT COLOR=#0000FF> </FONT>Year-to-date gross margin was 57.5% compared to<FONT COLOR=#0000FF> </FONT>55.4% in the same period last year. </P>
<P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std"><B>Second-Quarter Highlights</B></P>
<P style="line-height:16pt; margin:0pt"><BR></P>
<P style="margin-top:0pt; margin-bottom:-12pt; padding-left:36pt; text-indent:-18pt; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
<P style="line-height:17pt; margin:0pt; padding-left:36pt; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">Second-quarter basic earnings from continuing operations were $1.22 per share, or $1.20 per share on a diluted basis, compared to $0.71 and $0.69, respectively, during the same period of last year. </FONT></P>
<P style="margin-top:0pt; margin-bottom:-12pt; padding-left:36pt; text-indent:-18pt; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
<P style="line-height:17pt; margin:0pt; padding-left:36pt; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">As a result of a settlement reached with bioM&#233;rieux, Bio-Rad reported additional revenue in the second quarter of $11.7 million in royalties and licensing fees. &nbsp;</FONT></P>
<P style="margin-top:0pt; margin-bottom:-12pt; padding-left:36pt; text-indent:-18pt; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
<P style="line-height:17pt; margin:0pt; padding-left:36pt; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">Life Science segment net sales for the quarter were</FONT><FONT COLOR=#0000FF> </FONT>$134.4 million, up somewhat from $133.1 million reported in the second quarter of last year. Sales in this area increased by 1.0% or 1.8% excluding currency effects over the same period last year. &nbsp;</P>
<P style="margin:0pt" align=justify><BR></P>
<P style="margin:0pt; font-family:HelveticaNeueLT Std" align=center>(more)</P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt; font-family:HelveticaNeueLT Std"><B><I>Bio-Rad Reports Second-Quarter Results</I></B></P>
<P style="line-height:17pt; margin:0pt; font-family:HelveticaNeueLT Std"><B><I>Page 2</I></B></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR>
<BR></P>
<P style="margin-top:0pt; margin-bottom:-12pt; padding-left:36pt; text-indent:-18pt; font-family:Symbol; page-break-before:always"><FONT FACE="Symbol">&#183;</FONT></P>
<P style="line-height:17pt; margin:0pt; padding-left:36pt; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">The Clinical Diagnostics segment reported sales of $180.2 million, a 16.1% increase over the same period last year of $155.2 million. On a currency-neutral basis, segment sales increased 16.6%. Excluding the bioM&#233;rieux settlement, currency-neutral sales increased by 8.9%. </FONT></P>
<P style="margin-top:0pt; margin-bottom:-12pt; padding-left:36pt; text-indent:-18pt; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
<P style="line-height:17pt; margin:0pt; padding-left:36pt; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">In April, the Company announced that it had signed a multi-year agreement in which Premier, one of the largest group purchasing organizations in the United States, had agreed to a three-year sole-source contract with Bio-Rad covering diabetes monitoring instrumentation and products. </FONT></P>
<P style="margin-top:0pt; margin-bottom:-12pt; padding-left:36pt; text-indent:-18pt; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
<P style="line-height:17pt; margin:0pt; padding-left:36pt; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">During the quarter, Cell Signaling Technology (CST) and Bio-Rad entered into a partnership agreement in which CST will develop a broad array of antibody assays that will run on the Bio-Plex</FONT><SUP>&#174; </SUP>suspension array system.</P>
<P style="line-height:16pt; margin:0pt" align=center><BR></P>
<P style="line-height:17pt; margin:0pt; font-family:HelveticaNeueLT Std">Life Science segment net sales for the quarter were<FONT COLOR=#0000FF> </FONT>$134.4 million, up 1.0% compared to $133.1 million in the second quarter last year. On a currency-neutral basis, sales increased by 1.8%. Performance in this segment was the result of a number of factors including sales of amplification reagents, process chromatography media and the Bio-Plex<SUP>&#174;</SUP> suspension array system, which continue to show impressive growth worldwide. These results were somewhat tempered, however, by the continued erosion of BSE testing revenue as well as increased competition in real-time instrument sales worldwide. During the second quarter, the Company launched iQ-Check<SUP>&#174; </SUP>tests, a series of rapid food diagnostic tests based on a<B> </B>quantitative PCR (polymerase chain reaction) platform. The new tests are both sensitive and specific allowing for the detection of common food pathogens in less than 24 hours. 
&nbsp;</P>
<P style="margin:0pt"><BR></P>
<P style="line-height:17pt; margin:0pt; font-family:HelveticaNeueLT Std">The Clinical Diagnostics segment reported sales of $180.2 million, a 16.1% increase over the second quarter last year of $155.2 million. On a currency-neutral basis, segment sales increased 16.6%. These results are due in part to growth across the product line in addition to the bioM&#233;rieux settlement. In April, the Company introduced the Platelia<SUP>&#8482;</SUP> Dengue NS1 Ag Assay for dengue screening. The test provides early diagnosis of dengue acute infections, a tropical disease transmitted to humans from mosquitoes. Also during April, the Company launched a diagnostic test for celiac disease, an autoimmune disorder characterized by individuals having abnormal reactions to gluten, a protein found in wheat, barley, and rye. &nbsp;</P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="line-height:16pt; margin:0pt" align=center><BR></P>
<P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std" align=center>(more)</P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt; font-family:HelveticaNeueLT Std"><B><I>Bio-Rad Reports Second-Quarter Results</I></B></P>
<P style="margin:0pt; font-family:HelveticaNeueLT Std"><B><I>Page 3</I></B></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR>
<BR></P>
<P style="line-height:17pt; margin:0pt; font-family:HelveticaNeueLT Std; page-break-before:always">&#147;We are pleased to report overall solid financial performance during the first half of the year,&#148; said Norman Schwartz, Bio-Rad President and Chief Executive Officer. &#147;As the year progresses, we will continue to pursue targeted opportunities to expand the business and improve operational efficiencies.&#148;</P>
<P style="margin:0pt"><BR></P>
<P style="line-height:17pt; margin:0pt; font-family:HelveticaNeueLT Std">Management will discuss these results in a conference call at 2 p.m. Pacific Daylight Time (5 p.m. Eastern Daylight Time) August 3, 2006.<FONT COLOR=#0000FF> </FONT>Interested parties can access the call by dialing 866-356-4123 (in the U.S.), or<FONT COLOR=#0000FF> </FONT>617-597-5393 (international),<FONT COLOR=#0000FF> </FONT>access number 58346209.<FONT COLOR=#0000FF> &nbsp;</FONT>The live webcast can be accessed at http://www.bio-rad.com. A replay of the call will be available at<FONT COLOR=#0000FF> </FONT>888-286-8010 (in the U.S.), or 617-801-6888 (international), access number 74549276, for seven days following the call and the webcast can be accessed at http://www.bio-rad.com for 30 days.</P>
<P style="margin:0pt"><BR></P>
<P style="line-height:17pt; margin:0pt; font-family:HelveticaNeueLT Std"><B>About Bio-Rad</B></P>
<P style="line-height:17pt; margin:0pt; font-family:HelveticaNeueLT Std">Bio-Rad Laboratories, Inc., is a multinational manufacturer and distributor of life science research and clinical diagnostics products. Based in Hercules, California, Bio-Rad serves more than 70,000 research and industry customers worldwide through a network of more than 30 wholly owned subsidiary offices. For more information, please visit www.bio-rad.com.</P>
<P style="margin:0pt"><BR></P>
<P style="line-height:11pt; margin:0pt; font-family:HelveticaNeueLT Std; font-size:9pt"><I>Various statements made within this press release may constitute &#147;forward-looking statements&#148; for purposes of the Securities and Exchange Commission&#146;s &#147;safe harbor&#148; provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. The forward-looking statements contained herein involve risks and uncertainties that could cause results to differ materially from the Company&#146;s expectations.</I></P>
<P style="margin:0pt" align=justify><BR></P>
<P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std"><B>For more information contact:</B></P>
<P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std">Christine Tsingos, Vice President and Chief Financial Officer, or</P>
<P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std">Ron Hutton, Treasurer</P>
<P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std">Bio-Rad Laboratories, Inc.</P>
<P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std">510-724-7000</P>
<P style="line-height:16pt; margin:0pt; font-family:HelveticaNeueLT Std">investor_relations@bio-rad.com</P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR>
<BR></P>
<P style="margin:0pt; page-break-before:always"><BR></P>
<P style="margin:0pt" align=right><BR></P>
<TABLE style="font-size:10pt" cellspacing=0><TR><TD width=239.5></TD><TD width=55.9></TD><TD width=9></TD><TD width=53.75></TD><TD width=9></TD><TD width=58.25></TD><TD width=9.25></TD><TD width=53.25></TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="line-height:11pt; margin:0pt; font-size:9pt" align=center><FONT FACE="Times New Roman">BIO-RAD LABORATORIES, INC.</FONT></P>
</TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="line-height:11pt; margin:0pt; font-size:9pt" align=center>Condensed Consolidated Statements of Income</P>
</TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="line-height:11pt; margin:0pt; font-size:9pt" align=center>(In thousands, except per share data)</P>
</TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="line-height:11pt; margin:0pt; font-size:9pt" align=center>(Unaudited)</P>
</TD></TR>
<TR><TD valign=top width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=158.2 colspan=3><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=12><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=161 colspan=3><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=158.2 colspan=3><P style="line-height:11pt; margin:0pt; font-size:9pt" align=center>Three Months Ended</P>
<P style="line-height:11pt; margin:0pt; font-size:9pt" align=center>June 30,</P>
</TD><TD valign=top width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=161 colspan=3><P style="line-height:11pt; margin:0pt; font-size:9pt" align=center>Six Months Ended</P>
<P style="line-height:11pt; margin:0pt; font-size:9pt" align=center>June 30,</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=center>2006</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=center>2005</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=center>2006</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=center>2005</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; font-size:9pt">Net sales</P>
</TD><TD width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;317,747&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;291,302&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;626,085&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;590,473&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; text-indent:14.4pt; font-size:9pt">Cost of goods sold</P>
</TD><TD style="border-bottom:0.5pt solid #000000" width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>133,085&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>130,659&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>265,895&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>263,424&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; font-size:9pt">Gross profit</P>
</TD><TD width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>184,662&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>160,643&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>360,190&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>327,049&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; font-size:9pt">Selling, general and administrative expense</P>
</TD><TD width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>110,466&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>104,222&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>210,536&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>203,720&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; font-size:9pt">Product research and development expense</P>
</TD><TD width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>30,971&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>28,499&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>59,062&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>55,322&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; font-size:9pt">Interest expense</P>
</TD><TD width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>7,880&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>8,044&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>15,899&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>16,161&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; font-size:9pt">Foreign exchange (gains) losses, net</P>
</TD><TD width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>1,241&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>(922)</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>1,252&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>(1,199)</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; font-size:9pt">Other (income) expense, net</P>
</TD><TD width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>(7,753)</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>(4,689)</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>(12,295)</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>(10,527)</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; font-size:9pt">Income from continuing operations before taxes</P>
</TD><TD style="border-top:0.5pt solid #000000" width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>41,857&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>25,489&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>85,736&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>63,572&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; text-indent:14.4pt; font-size:9pt">Provision for income taxes</P>
</TD><TD style="border-bottom:0.5pt solid #000000" width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>9,591&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>7,101&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>22,272&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>15,664&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; font-size:9pt">Income from continuing operations</P>
</TD><TD width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>32,266&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>18,388&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>63,464&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>47,908&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; text-indent:14.4pt; font-size:9pt">Discontinued operations (net of tax)</P>
</TD><TD style="border-bottom:0.5pt solid #000000" width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>--&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>--&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>--&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>3,974&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; font-size:9pt">Net income</P>
</TD><TD style="border-bottom:2pt double #000000" width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;32,266&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18,388&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;63,464&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;51,882&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; font-size:9pt">Basic earnings per share:</P>
</TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; text-indent:14.4pt; font-size:9pt">Continuing operations</P>
</TD><TD width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;1.22&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;0.71&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;2.41&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;1.85&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; text-indent:14.4pt; font-size:9pt">Discontinued operations</P>
</TD><TD style="border-bottom:0.5pt solid #000000" width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>--&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>--&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>--&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>0.15&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; text-indent:14.4pt; font-size:9pt">Net income</P>
</TD><TD style="border-bottom:2pt double #000000" width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;1.22&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;0.71&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;2.41&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;2.00&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; text-indent:14.4pt; font-size:9pt">Weighted average common shares</P>
</TD><TD style="border-bottom:2pt double #000000" width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>26,341&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>26,020&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>26,309&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>25,965&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; font-size:9pt">Diluted earnings per share:</P>
</TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; text-indent:14.4pt; font-size:9pt">Continuing operations</P>
</TD><TD width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;1.20&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;0.69&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;2.36&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;1.80&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; text-indent:14.4pt; font-size:9pt">Discontinued operations</P>
</TD><TD style="border-bottom:0.5pt solid #000000" width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>--&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>--&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>--&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>0.15&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; text-indent:14.4pt; font-size:9pt">Net income</P>
</TD><TD style="border-bottom:2pt double #000000" width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;1.20&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;0.69&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;2.36&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;1.95&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:11pt; margin:0pt; text-indent:14.4pt; font-size:9pt">Weighted average common shares</P>
</TD><TD style="border-bottom:2pt double #000000" width=74.533><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>26,900&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=71.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>26,610&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=77.667><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>26,865&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=71><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>26,583&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=650.533 colspan=8><P style="line-height:11pt; margin:0pt; font-size:9pt">The accompanying notes are an integral part of these consolidated financial statements.</P>
</TD></TR>
</TABLE>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt" align=center><BR>
<BR></P>
<P style="margin:0pt; padding-left:-36pt; padding-right:-49pt; font-size:9pt; page-break-before:always" align=center>BIO-RAD LABORATORIES, INC</P>
<P style="margin:0pt; font-size:9pt" align=center>Condensed Consolidated Balance Sheets</P>
<P style="margin:0pt; font-size:9pt" align=center>(In thousands)</P>
<P style="margin:0pt; font-size:9pt" align=center>(Unaudited)</P>
<TABLE style="font-size:10pt" cellspacing=0><TR><TD width=320></TD><TD width=18.6></TD><TD width=55.8></TD><TD width=12.5></TD><TD width=66.5></TD></TR>
<TR><TD width=426.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=74.4><P style="line-height:9pt; margin:0pt; font-size:9pt" align=center>June 30,</P>
<P style="line-height:9pt; margin:0pt; font-size:9pt" align=center>2006</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=88.667><P style="line-height:9pt; margin:0pt; font-size:9pt" align=center>December 31, 2005</P>
</TD></TR>
<TR><TD valign=top width=426.667><P style="margin:0pt; font-size:9pt">Current assets: </P>
</TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=74.4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=426.667><P style="margin:0pt; padding-left:14.4pt; font-size:9pt">Cash and cash equivalents &nbsp;</P>
</TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=74.4><P style="margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;245,646&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;296,716&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=426.667><P style="margin:0pt; padding-left:14.4pt; font-size:9pt">Restricted cash</P>
</TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=74.4><P style="margin:0pt; font-size:9pt" align=right>--&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>36,138&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=426.667><P style="margin:0pt; padding-left:14.4pt; font-size:9pt">Short-term investments</P>
</TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=74.4><P style="margin:0pt; font-size:9pt" align=right>188,319&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>116,343&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=426.667><P style="margin:0pt; padding-left:14.4pt; font-size:9pt">Accounts receivable, net </P>
</TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=74.4><P style="margin:0pt; font-size:9pt" align=right>273,014&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>247,192&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=426.667><P style="margin:0pt; padding-left:14.4pt; font-size:9pt">Inventories, net </P>
</TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=74.4><P style="margin:0pt; font-size:9pt" align=right>244,339&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>212,342&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=426.667><P style="margin:0pt; padding-left:14.4pt; font-size:9pt">Other current assets</P>
</TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=74.4><P style="line-height:11pt; margin:0pt; font-size:9pt" align=right>106,855&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=88.667><P style="margin:0pt; font-size:9pt" align=right>99,480&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=426.667><P style="margin:0pt; text-indent:21.6pt; font-size:9pt">Total current assets </P>
</TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=74.4><P style="margin:0pt; font-size:9pt" align=right>1,058,173&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>1,008,211&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=426.667><P style="margin:0pt; font-size:9pt">Net property, plant and equipment </P>
</TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=74.4><P style="margin:0pt; font-size:9pt" align=right>183,783&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>180,258&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=426.667><P style="margin:0pt; font-size:9pt">Goodwill </P>
</TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=74.4><P style="margin:0pt; font-size:9pt" align=right>113,276&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>113,276&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=426.667><P style="margin:0pt; font-size:9pt">Purchased intangibles, net</P>
</TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=74.4><P style="margin:0pt; font-size:9pt" align=right>26,238&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>28,449&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=426.667><P style="margin:0pt; font-size:9pt">Other assets </P>
</TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=74.4><P style="margin:0pt; font-size:9pt" align=right>112,566&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>96,388&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=426.667><P style="margin:0pt; text-indent:21.6pt; font-size:9pt">Total assets</P>
</TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=74.4><P style="margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;1,494,036&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=88.667><P style="margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,426,582&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=426.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=74.4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=426.667><P style="margin:0pt; font-size:9pt">Current liabilities:</P>
</TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=74.4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=426.667><P style="margin:0pt; padding-left:14.4pt; font-size:9pt">Notes payable and current maturities of long-term debt</P>
</TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=74.4><P style="margin:0pt; font-size:9pt" align=right>4,478&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>3,341&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=426.667><P style="margin:0pt; padding-left:14.4pt; font-size:9pt">Accounts payable</P>
</TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=74.4><P style="margin:0pt; font-size:9pt" align=right>&nbsp;69,302&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>&nbsp;72,950&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=426.667><P style="margin:0pt; padding-left:14.4pt; font-size:9pt">Accrued payroll and employee benefits</P>
</TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=74.4><P style="margin:0pt; font-size:9pt" align=right>76,980&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>81,076&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=426.667><P style="margin:0pt; padding-left:14.4pt; font-size:9pt">Sales, income and other taxes payable</P>
</TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=74.4><P style="margin:0pt; font-size:9pt" align=right>19,396&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>15,841&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=426.667><P style="margin:0pt; padding-left:14.4pt; font-size:9pt">Other current liabilities</P>
</TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=74.4><P style="margin:0pt; font-size:9pt" align=right>110,865&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>146,035&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=426.667><P style="margin:0pt; text-indent:21.6pt; font-size:9pt">Total current liabilities</P>
</TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=74.4><P style="margin:0pt; font-size:9pt" align=right>281,021&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>319,243&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=426.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=74.4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=426.667><P style="margin:0pt; font-size:9pt">Long-term debt, net of current maturities</P>
</TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=74.4><P style="margin:0pt; font-size:9pt" align=right>425,873&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>425,687&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=426.667><P style="margin:0pt; font-size:9pt">Other long-term liabilities</P>
</TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=74.4><P style="margin:0pt; font-size:9pt" align=right>31,028&nbsp;</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="margin:0pt; font-size:9pt" align=right>23,678&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=426.667><P style="margin:0pt; font-size:9pt">Stockholders&#146; equity</P>
</TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=74.4><P style="margin:0pt; font-size:9pt" align=right>756,114&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=88.667><P style="margin:0pt; font-size:9pt" align=right>657,974&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=426.667><P style="margin:0pt; text-indent:28.8pt; font-size:9pt">Total liabilities and stockholders&#146; equity</P>
</TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=74.4><P style="margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;1,494,036&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=88.667><P style="margin:0pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,426,582&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=426.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=24.8><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=74.4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=88.667><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=631.2 colspan=5><P style="margin:0pt; font-size:9pt">The accompanying notes are an integral part of these consolidated financial statements.</P>
</TD></TR>
</TABLE>
<P style="line-height:11pt; margin-top:0pt; margin-bottom:4.5pt; font-size:9pt">&nbsp;</P>
<P style="margin-top:0pt; margin-bottom:4.5pt"><BR>
<BR></P>
<P style="margin-top:0pt; margin-bottom:4.5pt; page-break-before:always"><BR></P>
<TABLE style="font-size:10pt" cellspacing=0><TR><TD width=284.75></TD><TD width=53.65></TD><TD width=12.5></TD><TD width=50.85></TD></TR>
<TR><TD valign=top width=535.667 colspan=4><P style="line-height:10pt; margin:0pt; font-size:9pt" align=center>BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
<TR><TD valign=top width=535.667 colspan=4><P style="line-height:10pt; margin:0pt; font-size:9pt" align=center>Condensed Consolidated Statements of Cash Flows</P>
</TD></TR>
<TR><TD valign=top width=535.667 colspan=4><P style="line-height:10pt; margin:0pt; font-size:9pt" align=center>(In thousands)</P>
</TD></TR>
<TR><TD valign=top width=535.667 colspan=4><P style="line-height:10pt; margin:0pt; font-size:9pt" align=center>(Unaudited) &nbsp;</P>
</TD></TR>
<TR><TD valign=top width=379.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=71.533><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=379.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=156 colspan=3><P style="line-height:10pt; margin:0pt; font-size:9pt" align=center>Six Months Ended</P>
</TD></TR>
<TR><TD valign=top width=379.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=156 colspan=3><P style="line-height:10pt; margin:0pt; font-size:9pt" align=center>June 30,</P>
</TD></TR>
<TR><TD valign=top width=379.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=71.533><P style="line-height:10pt; margin:0pt; font-size:9pt" align=center>2006</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" valign=top width=67.8><P style="line-height:10pt; margin:0pt; font-size:9pt" align=center>2005</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt">Cash flows from operating activities:</P>
</TD><TD width=71.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Cash received from customers</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;612,996&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;583,459&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Cash paid to suppliers and employees</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(549,519)</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(527,665)</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Interest paid</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(15,403)</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(15,459)</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Income tax payments</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(2,620)</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(20,161)</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Litigation settlement related to MJ acquisition</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(44,960)</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>--&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Other operating activities</P>
</TD><TD style="border-bottom:0.5pt solid #000000" width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>10,998&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>7,644&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Net cash provided by operating activities</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>11,492&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>27,818&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt">Cash flows from investing activities:</P>
</TD><TD width=71.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Capital expenditures, net</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(24,851)</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(17,591)</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Receipt (payment) of restricted cash</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>36,138&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(35,565)</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Other investing activities </P>
</TD><TD style="border-bottom:0.5pt solid #000000" width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(83,043)</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>76,150&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Net cash provided by (used in) investing activities</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(71,756)</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>22,994&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt">Cash flows from financing activities:</P>
</TD><TD width=71.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Proceeds from issuance of common stock</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>5,467&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>4,516&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Other financing activities</P>
</TD><TD style="border-bottom:0.5pt solid #000000" width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>1,068&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>576&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Net cash provided by financing activities</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>6,535&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>5,092&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt">Effect of exchange rate changes on cash</P>
</TD><TD style="border-bottom:0.5pt solid #000000" width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>2,659&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>494&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt">Net increase (decrease) in cash and cash equivalents</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(51,070)</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>56,398&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt">Cash and cash equivalents at beginning of period</P>
</TD><TD style="border-bottom:0.5pt solid #000000" width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>296,716&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>195,734&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt">Cash and cash equivalents at end of period</P>
</TD><TD style="border-bottom:2pt double #000000" width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;245,646&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;252,132&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=451.2 colspan=2><P style="line-height:11pt; margin:0pt; font-size:9pt">Reconciliation of net income to net cash provided by operating activities:</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin:0pt; padding-left:14.4pt; font-size:9pt">Net income </P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;63,464&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;51,882&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Adjustments to reconcile net income to net cash provided by</P>
</TD><TD width=71.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:3.75pt; padding-left:28.8pt; font-size:9pt">operating activities:</P>
</TD><TD width=71.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Depreciation and amortization</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>26,436&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>30,091&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Changes in working capital</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(46,749)</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(45,925)</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Litigation settlement related to MJ acquisition</P>
</TD><TD width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(44,960)</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>--&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; padding-left:14.4pt; font-size:9pt">Other</P>
</TD><TD style="border-bottom:0.5pt solid #000000" width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>13,301&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:0.5pt solid #000000" width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>(8,230)</P>
</TD></TR>
<TR><TD width=379.667><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt">Net cash provided by operating activities</P>
</TD><TD style="border-bottom:2pt double #000000" width=71.533><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11,492&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2pt double #000000" width=67.8><P style="line-height:11pt; margin-top:0pt; margin-bottom:0.75pt; font-size:9pt" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27,818&nbsp;</P>
</TD></TR>
<TR><TD width=379.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=379.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=451.2 colspan=2><P style="line-height:11pt; margin:0pt; font-size:9pt">The accompanying notes are an integral part of these consolidated financial statements.</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=67.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="margin:0pt"><BR></P>
<P style="margin:0pt"><BR>
<BR></P>
</DIV></BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
